Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. - Wikidata - wikimedia - TriplyDB

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

http://www.wikidata.org/entity/Q34959906

about

Translatability scoring in drug development: eight case studies Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma State of the science: an update on renal cell carcinoma T cell receptor gene therapy for cancer Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Immune checkpoint inhibitor therapy associated hypophysitis Therapeutic cancer vaccines: past, present, and future From bench to bedside: immunotherapy for prostate cancer Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience Antibody-based immunotherapy for ovarian cancer: where are we at?Tumor infiltrating lymphocytes in ovarian cancer The enduring tale of T cells in HIV immunopathogenesis The blockade of immune checkpoints in cancer immunotherapy Targeting immune checkpoints in malignant glioma Update on immune checkpoint inhibitors in gynecological cancers Imaging Biomarkers in Immunotherapy Targeted immune therapy of ovarian cancer Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network Opening the door to innovation Immunosuppressive networks in the tumour environment and their therapeutic relevance Immunosuppressive strategies that are mediated by tumor cells Ipilimumab: from preclinical development to future clinical perspectives in melanoma.Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial Interface of signal transduction inhibition and immunotherapy in melanoma.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.Antibody Therapies in Cancer.Antibodies as therapeutic agents: vive la renaissance!Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.CTLA4 blockade broadens the peripheral T-cell receptor repertoire Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival.

P2860

Q22241760-8471902B-F394-476B-865D-8D34ED7AAF46 Q24559442-1EDFAE78-08BB-4D13-A5D2-9683EDA68477 Q24618690-5D6C1BD1-622A-4F59-80F3-4B687C2351D9 Q24630685-3D9E84EC-59FC-4E0C-8639-B2DF53CDBDCB Q24634774-D755E581-473A-48F0-91F9-8319923E31F3 Q24679736-CF9E42BE-3894-4D50-AA6E-739A11ABB77B Q24796946-5C0B800F-9D60-4681-9B74-776C007BCFD0 Q26742047-C4D131AA-1499-4526-AE38-FFF4C66A308C Q26775034-882C3C63-75F6-4350-90EE-D51381326529 Q26781098-F457D374-DDE8-4ED6-A170-9B7346D3A093 Q26799812-51172729-08D4-41FB-B9BE-8091A97317C9 Q26824310-AA37062F-8DC6-4BDB-8D91-6EA9DEFABFD1 Q26827140-1571D47B-032D-4A09-9043-CCF55802E5F4 Q26863283-0C868942-C35C-470F-AE3F-1DC25B13A4F8 Q26864390-75B54198-B15C-4609-A1EB-A1920D187BC3 Q26995499-EDA27726-8510-4514-9A84-E1BA268208B5 Q27000514-BD080C82-8DA7-432D-9D80-DC44FD319FFC Q27021878-CE505C2A-0CCB-42F4-B4E5-20518C5A30E2 Q27025707-211EB70D-B09D-4FE3-A99F-4195F2B6E664 Q27860852-2EFC63ED-AC9C-4724-B4A0-E3CA52FB9C95 Q28072012-E5706162-ACD7-400B-A4B1-D1DD16CC8CAC Q28076497-579413C6-866D-42AA-B2EE-B5873A26D225 Q28079871-D3E7DC15-8440-496A-B93A-7531772302CC Q28082828-41769B85-F5F3-426D-A17C-EC91CDBE8AB5 Q28271806-3B052CC9-1077-4662-850F-42F0EF86E13A Q28485085-0583C275-785C-430F-A958-2EC17D2BAE83 Q28655591-410630AF-F208-419C-8BD8-0AC31AEE3434 Q29619244-BDBF5E86-2876-4897-9004-3F6FCAC12EED Q29636247-B1D28045-026C-4DB1-884D-8B724A7FEB02 Q30240751-92DD26AA-A3BF-4AB3-B48E-46CB3FFCDCAF Q30407940-C9BE4FA1-2CF5-49DA-9A57-8F7C939AEAED Q30429380-DFC1B21F-077F-440B-B39E-D487D4E128B4 Q30438965-EF53EC1F-2041-4380-993E-9CDB14C1D6E0 Q30641952-BD3B4D77-E046-4968-847C-7941B9549BFA Q31104000-55B0D953-E295-4590-A186-0620CF403065 Q33193524-F298AEE8-E822-4BD0-BC53-92C8EC1D5FB7 Q33357295-C56C8995-8718-4D8C-854E-B2714656EA2B Q33384384-1B4C9A82-F36D-47E7-8252-4C6DC8A16232 Q33560753-093FB0F4-0780-4082-BFF2-04FB958E94D2 Q33564510-C1981345-8AA1-4138-AAEE-4283AB80C899

P2860

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

http://www.wikidata.org/entity/Q34959906

description

2003 nî lūn-bûn

@nan

2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@ast

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@en

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@nl

type

label

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@ast

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@en

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@nl

prefLabel

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@ast

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@en

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@nl

P1433

Q34959906-F4A23DA0-1DB6-499C-8CA3-47D1A61FDA18

P1476

Q34959906-9B2CBB57-C8D7-4E23-A1FA-592D7880D107

P2093

Q34959906-06F9F2D8-5544-4199-AA7C-581F564ED799

Q34959906-0D5CB186-B5FC-4874-A4DC-54351F0B67A1

Q34959906-117DB32F-7B6B-45ED-A763-45A391B260D3

Q34959906-2E550B24-EE75-42E1-B66E-9B1468823EB7

Q34959906-3143E600-9A03-4FE7-8F61-881D85DBE8B2

Q34959906-39B8ED3B-7DF1-4E0D-A696-4B5BFC8A2BC7

Q34959906-627B381A-FA5A-4B5A-88DD-AED3AE42748B

Q34959906-6659076D-D3BD-46EC-B30D-9792549F25DD

Q34959906-7DD1B3FA-D9BF-46A9-A0D4-B105E5CADAA5

Q34959906-917FD80B-6108-4EFE-BC52-499593945486

P2860

Q34959906-00018C82-9E39-49DF-A4B0-466BAAC5F8AD

Q34959906-04C1862C-2840-437A-9E0C-02A0A96E6F29

Q34959906-05078F1C-AA9D-4A1E-BA29-148D8C54D260

Q34959906-08666838-F3CB-4FE8-8CD1-4C78856EDD27

Q34959906-0ECD8EA4-7245-433C-AC39-86ABB65E55CE

Q34959906-10E29359-283F-4E78-A2D9-7218209DE8C6

Q34959906-1781AB72-B330-450B-A470-930B3A3B5CC3

Q34959906-23E32C47-35B5-49B4-A266-B9911DDB41BA

Q34959906-26C88E4E-7185-4521-9117-0E99CC0C98E6

Q34959906-2766CF5A-8A05-4F6D-A2D0-A8DD04E3AF34

P304

Q34959906-C9534CC6-3B5A-481A-86E0-2A172A6424F8

P31

Q34959906-53031152-9F0C-4140-9A0F-64D8C8E5BB50

P356

Q34959906-F7BAFA50-3836-49E8-82B8-C25570B909F3

P407

Q34959906-6DBBF130-7EBB-40F6-B4D7-7B8D6C203E57

P433

Q34959906-D59442C1-CEC1-4FD1-AE57-81748AD30A33

P478

Q34959906-6305A503-5B91-45C0-A477-EA15D7CF9B9F

P50

Q34959906-55C9F79D-F665-415A-BAA3-83FD5C0EC4CF

Q34959906-FF0F6A06-8E39-45ED-8CBF-6DF60FE300DD

P577

Q34959906-5C0DF382-3B05-4DF0-9E33-A9364C581E42

P5875

Q34959906-EBCB46A2-32BF-429E-84E5-5D27FB44B85C

P698

Q34959906-DC18A461-0CFF-4EB5-B863-F1C447641D86

P921

Q34959906-A44E29CC-5979-4964-8B82-F17CD67495FC

Q34959906-D44855AE-CEAC-4196-B0E6-C34526118609

Q34959906-DEF56586-DA74-46D8-BCF9-44D944CECA7B

P932

Q34959906-E6E1F9CF-22B1-40FB-A830-5476724DD6F2

P356

PNAS.0830997100

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Biologic activity of cytotoxic ...... nd ovarian carcinoma patients.

@en

P2093

Alan Korman

http://www.w3.org/2001/XMLSchema#string

Ann Willman

http://www.w3.org/2001/XMLSchema#string

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Frank G Haluska

http://www.w3.org/2001/XMLSchema#string

Glenn Dranoff

http://www.w3.org/2001/XMLSchema#string

Marcus Butler

http://www.w3.org/2001/XMLSchema#string

Martin C Mihm

http://www.w3.org/2001/XMLSchema#string

Michael T Jaklitsch

http://www.w3.org/2001/XMLSchema#string

Michael V Seiden

http://www.w3.org/2001/XMLSchema#string

Robert J Soiffer

http://www.w3.org/2001/XMLSchema#string

P2860

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.

Human neoplasms elicit multiple specific immune responses in the autologous host

Human tumor antigens recognized by T lymphocytes

Dendritic cells and the control of immunity

Enhancement of antitumor immunity by CTLA-4 blockade

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

P304

4712-4717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0830997100

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

James P. Allison

P577

2003-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10816702

http://www.w3.org/2001/XMLSchema#string

P698

12682289

http://www.w3.org/2001/XMLSchema#string

P921

P932

153621

http://www.w3.org/2001/XMLSchema#string